Mouse Model News and Research

RSS

Study describes IgG antibodies in Crohn's disease specific for human bacterial flagellins

Last year, Charles O. Elson, M.D., demonstrated a potential preventive treatment for Crohn's disease, a form of inflammatory bowel disease. He used a mouse model that included immune-reactive T cells from patients with Crohn's disease in a flagellin peptide-specific immunotherapy.

6 May 2021

Novel CBD analog alleviates pain in mouse model of chemotherapy-induced peripheral neuropathy

For patients with chronic pain, ineffective treatments, lowered work productivity, and other factors often coalesce, fueling feelings of hopelessness and anxiety and setting the stage for even bigger problems, including substance use disorders.

5 May 2021

4D printing strategy helps fabricate biomimetic microchannel scaffold for spinal fusion

Spinal fusion is frequently performed to restore spinal stability in patients with spinal diseases, such as spinal stenosis, vertebral fractures, progressive deformities, and instability.

5 May 2021

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Researchers in the United States have identified short peptide sequences in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are immunogenic in a mouse model and may provide protection against viral variants.

5 May 2021

Researchers use gene therapy to prevent learning, memory loss in Alzheimer's mouse model

Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, have used gene therapy to prevent learning and memory loss in a mouse model of Alzheimer's disease (AD), a key step toward eventually testing the approach in humans with the neurodegenerative disease.

5 May 2021

New approach could revolutionize the treatment of liver diseases

Researchers from Niigata University , the University of Tokyo, Osaka University and Tokyo Medical University, Japan have developed a new approach that could revolutionize the treatment, prevention, and possibly reversal of the damages caused by liver diseases.

3 May 2021

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

Researchers in the United States and Austria have demonstrated the potential of a modified influenza virus as a vaccine to protect against viral respiratory pathogens, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

2 May 2021

Correcting mutations in muscle stem cells using new gene-editing technology

A new gene-editing technique can be used to correct mutations in muscle stem cells, paving the way for the first potential cell therapy for genetic muscle disorders.

30 Apr 2021

New study reveals mechanisms that result in lethal COVID-19

A new study is drawing the most detailed picture yet of SARS-CoV-2 infection in the lung, revealing mechanisms that result in lethal COVID-19, and may explain long-term complications and show how COVID-19 differs from other infectious diseases.

30 Apr 2021

Pancreatic cancer cells de-differentiate to spawn highly aggressive tumors, study shows

A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert-or "de-differentiate"-to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.

29 Apr 2021

New research sheds light on what causes sudden unexpected death in epilepsy

New research from the University of Virginia School of Medicine has shed light on the No. 1 cause of epilepsy deaths, suggesting a long-sought answer for why some patients die unexpectedly following an epileptic seizure.

28 Apr 2021

UCI biologists develop new mouse model to study late-onset Alzheimer's disease

University of California, Irvine biologists have developed a new genetically engineered mouse model that, unlike its predecessors, is based on the most common form of Alzheimer's disease.

27 Apr 2021

Researchers design "nanotraps" to capture and destroy SARS-CoV-2 viruses

Researchers at the Pritzker School of Molecular Engineering at the University of Chicago have designed a completely novel potential treatment for COVID-19: nanoparticles that capture SARS-CoV-2 viruses within the body and then use the body's own immune system to destroy it.

27 Apr 2021

CU Cancer Center researchers receive PRCRP grant to investigate metastasis

Two members of the University of Colorado Cancer Center have received prestigious Idea Awards from the U.S. Department of Defense's Peer Reviewed Cancer Research Program.

27 Apr 2021

Drug cocktail can effectively activate and expand muscle stem cells

Skeletal muscle – the type of muscle that attaches to bones and enables movement – is the most abundant tissue in the human body.

27 Apr 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021

Experimental drug reverses key symptoms of Alzheimer's disease in mice

Researchers at Albert Einstein College of Medicine have designed an experimental drug that reversed key symptoms of Alzheimer's disease in mice.

22 Apr 2021

Novel approach to gene editing bypasses disease-causing mutations in a gene

A new approach to gene editing using the CRISPR/Cas9 system bypasses disease-causing mutations in a gene, enabling treatment of genetic diseases linked to a single gene, such as cystic fibrosis, certain types of sickle cell anemia, and other rare diseases.

21 Apr 2021

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Study shows lipid nanoparticle-based siRNA is potent in suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – in cells as well as in mice models.

21 Apr 2021

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021